Antimicrobial resistance (AMR) kills 700,000 people annually worldwide — and the WHO's AMR action plan projects this will rise to 10 million annual deaths by 2050 if current trajectories continue. The CDC's 2022 report identified 18 AMR threats in the U.S., including carbapenem-resistant Enterobacterales (CRE), MRSA, VRE, and drug-resistant Candida auris — organisms for which few or no effective antibiotics remain. Antibiotic stewardship programs (ASPs) — hospital-based initiatives implementing evidence-based antibiotic prescribing — are now mandated by CMS for hospital accreditation and have demonstrated 15–35% reduction in antibiotic use without worsening patient outcomes or increasing mortality. Our laboratory supplies and diagnostic equipment sections support the clinical microbiology infrastructure that ASPs depend on.
Antibiotic Stewardship Program Core Elements
CDC's Core Elements of Hospital Antibiotic Stewardship Programs: (1) Leadership commitment (hospital administration and pharmacy/physician champion designation); (2) Accountability and expertise (physician and pharmacist ASP co-leadership with ID training); (3) Drug expertise (clinical pharmacist with ASP training involvement in prescribing decisions); (4) Action (implementing prospective audit and feedback, formulary restrictions, pre-authorization requirements for broad-spectrum antibiotics); (5) Tracking (antibiotic use surveillance using days of therapy/1000 patient days metric); (6) Reporting (regular feedback to prescribers on their antibiotic use patterns); (7) Education (on optimal antibiotic prescribing and resistance). Facilities implementing all elements achieve the most sustainable reductions.
Rapid Diagnostics: Enabling De-escalation
The fundamental challenge of antibiotic stewardship is that empirical broad-spectrum therapy is often initiated before culture results are available — and de-escalation to narrow-spectrum agents once sensitivities return is inconsistently performed. Rapid diagnostic technologies are changing this: PCR-based multiplex panels (BioMerieux BioFire FilmArray, Luminex VERIGENE) identify pathogen identity and resistance genes from blood culture bottles within 1–2 hours vs 48–72 hours for conventional culture. Procalcitonin (PCT) — a biomarker elevated in bacterial but not viral infection — guides antibiotic initiation in respiratory infections and antibiotic discontinuation when levels normalize (PCT-guided discontinuation reduces total antibiotic exposure by 20–30% in RCTs). Point-of-care CRP testing similarly supports strep/influenza distinction in primary care. Lab supplies supporting rapid diagnostics including culture media, blood culture bottles, and point-of-care test supplies are available through our laboratory supplies section.
